A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.

导出 OA

翻译打印收藏纠错

第一作者： Vaibhav,Sahai

第一单位： Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

作者： Vaibhav,Sahai ^[1] ; Kent A,Griffith ^[2] ; Muhammad S,Beg ^[3] ; Walid L,Shaib ^[4] ; Devalingam,Mahalingam ^[5] ; David B,Zhen ^[6] ; Dustin A,Deming ^[7] ; Mark M,Zalupski ^[1]

作者单位： Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. ^[1] Center for Cancer Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA. ^[2] Division of Hematology and Oncology, Department of Internal Medicine, University of Texas, Southwestern, Dallas, Texas, USA. ^[3] Department of Hematology and Oncology, Emory University, Atlanta, Georgia, USA. ^[4] Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, Illinois, USA. ^[5] Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, Washington, USA. ^[6] Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA. ^[7]

关键词 chemo immunotherapybiliary cancer cholangiocarcinoma immune checkpoint blockade immunotherapy